Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Stemirna COVID-19 vaccine

From Wikipedia, the free encyclopedia
Vaccine candidate against COVID-19

Pharmaceutical compound
Stemirna COVID-19 vaccine
Vaccine description
TargetSARS-CoV-2
Vaccine typemRNA
Clinical data
Other namesSW 0123
Routes of
administration
Intramuscular
Identifiers
CAS Number
Part ofa series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
virus iconCOVID-19 portal

Stemirna COVID-19 vaccine is aCOVID-19 vaccine candidate developed by Stemirna Therapeutics.[2][3] The Stemirna COVID-19 vaccine is labeled as a mRNA vaccine which means it causes the body to make a protein specific to the vaccine which triggers a immune response from the body.[4] Stemirna first started the production of vaccines in result of the COVID-19 pandemic, therefore the first vaccine the began producing was a COVID-19 vaccine.[5]

Research

[edit]

Testing on mice and other non human primates, the vaccine showed results that would lead the body to produce antibodies that would stop the spread and limit the coronavirus therefore the vaccine seemed very promising for human trials.[4] Stemirna explains that the research in Nanotechnology has been a big help into researching and create possible vaccines for the COVID-19 virus.[6]

History

[edit]

Stemirna Therapeutics raised a total of 1.2 Billion RMB (Renminbi) which translates to a little less than 200 million US Dollars for the start of their production and testing trials.[5] Li Hangwen, a co-founder of the company, stated they were confident in the vaccine's efficacy and safety based on ongoing Phase 1 and Phase 2 trial data conducted in Laos.[7] Stemirna Therapeutics first began their clinical trials in Brazil as part of its Phase 3 testing.[7] Li Hangwen, who is the chief executive of the company said that they were going to be able to produce 400 million doses of the vaccine each year.[7] The stemirna Vaccine uses nanotechnology which has helped to quickly create diagnostic tools, vaccines, and antiviral treatments for SARS-CoV-2.[6]


References

[edit]
  1. ^World Intellectual Property Organization. (2022).COVID-19-related vaccines and therapeutics: Preliminary insights on related patenting activity during the pandemic(PDF). Geneva: World Intellectual Property Organization.doi:10.34667/tind.45030.ISBN 978-92-805-3359-0.
  2. ^"Randomized, double-blind, placebo-controlled phase I clinical trial to evaluate the safety and immunogenicity of mRNACOVID-19 vaccine in healthy susceptible populations aged 18 years and older people".Chinese Clinical Trial Registry (ChiCTR). Archived fromthe original on 15 May 2021. Retrieved15 May 2021.
  3. ^Clinical trial numberNCT05144139 for "A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above" atClinicalTrials.gov
  4. ^abYang R, Deng Y, Huang B, Huang L, Lin A, Li Y, et al. (31 May 2021)."A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity".Signal Transduction and Targeted Therapy.6 (1) 213.doi:10.1038/s41392-021-00634-z.ISSN 2059-3635.PMC 8165147.PMID 34059617.
  5. ^abTaylor NP (4 June 2021)."China's Stemirna raises $188M to fund mRNA COVID-19 vaccine".www.fiercebiotech.com. Retrieved28 April 2025.
  6. ^abXu C, Lei C, Hosseinpour S, Ivanovski S, Walsh LJ, Khademhosseini A (29 September 2022)."Nanotechnology for the management of COVID-19 during the pandemic and in the post-pandemic era".National Science Review.9 (10) nwac124.doi:10.1093/nsr/nwac124.ISSN 2095-5138.PMC 9522393.PMID 36196115.
  7. ^abcKnowlton K (January 1998). "Retrieved icon, 1998".ACM SIGGRAPH 98 Electronic art and animation catalog. New York, NY, USA: ACM. p. 80.doi:10.1145/281388.281648.ISBN 1-58113-045-7.
logo
Development
Classes
Administration
Vaccines
Bacterial
Viral
Protozoan
Helminthiasis
Other
Inventors/
researchers
Controversy
Related
Pre-pandemic
2020
2021
2022
2023
Africa
Northern
Eastern
Southern
Central
Western
Asia
Central/North
East
Mainland China
South
India
By location
Southeast
Malaysia
Philippines
West
Europe
United Kingdom
By location
Eastern
Western Balkans
European Union
EFTA countries
Microstates
North
America
Atlantic
Canada
Caribbean
Countries
British Overseas Territories
Caribbean Netherlands
French West Indies
US insular areas
Central America
United States
responses
By location
Oceania
Australia
New Zealand
South
America
Others
Culture and
entertainment
Arts and
cultural heritage
Education
By country
Sports
By country
By sport
Society
and rights
Social impact
Labor
Human rights
Legal
Minority
Religion
Economic
By country
By industry
Supply and trade
Financial markets
Information
Misinformation
Politics
Political impact
Protests
International relations
Language
Others
Health issues
Medical topics
Testing and
epidemiology
Apps
Prevention
Vaccines
Topics
Authorized
DNA
Inactivated
mRNA
Subunit
Viral vector
Virus-like particles
In trials
Attenuated
DNA
Inactivated
RNA
Subunit
Viral vector
Virus-like particles
Deployment
by location
Africa
Asia
Europe
North America
Oceania
South America
Others
Treatment
Monoclonal antibodies
Small molecule antivirals
Specific
General
Institutions
Hospitals and
medical clinics
Mainland China
Others
Organizations
Health
institutes
Pandemic
institutes
Relief funds
People
Medical
professionals
Researchers
Officials
WHO
By location
Others
Data (templates)
Global
Africa
Americas
Asia
Europe
Oceania
Others
Portals:


Stub icon

This article about COVID-19 vaccines is astub. You can help Wikipedia byexpanding it.

Stub icon

This article aboutvaccines orvaccination is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Stemirna_COVID-19_vaccine&oldid=1317488982"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp